Foghorn Therapeutics (FHTX) said Monday it has decided to discontinue the independent development of FHD-286 in combination with decitabine to treat patients with relapsed and/or refractory acute myeloid leukemia.
The company is evaluating collaborations and investigator sponsored trials for advancing FHD-286, it said, adding that it will now prioritize investment in proprietary pipeline and Lilly partnership programs.
Foghorn said it had $267.4 million in cash, cash equivalents and, marketable securities as of Sept. 30 to support its operations through 2027.
Foghorn's stock fell more than 20% in recent Monday premarket activity.
Price: 4.23, Change: -1.07, Percent Change: -20.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。